Recently we demonstrated that the expression of VEGF by malignant CTCL cells is mediated by the aberrant activation of JAK3 and c-Jun N-terminal kinases (JNKs) [12]. This evidence concerns the gene JAK3 and primary cutaneous T-cell non-Hodgkin lymphoma.